(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 8.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Vertex Pharmaceuticals's revenue in 2025 is $11,418,800,000.On average, 35 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,134,375,708,475, with the lowest VRTX revenue forecast at $2,974,387,942,251, and the highest VRTX revenue forecast at $3,264,878,549,834. On average, 33 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,433,839,988,843, with the lowest VRTX revenue forecast at $2,999,514,226,049, and the highest VRTX revenue forecast at $3,865,858,235,778.
In 2027, VRTX is forecast to generate $3,735,099,003,768 in revenue, with the lowest revenue forecast at $2,970,542,082,486 and the highest revenue forecast at $4,306,850,155,498.